George A. Fisher Jr.
Publication Details
-
Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Cancer. 2005; (1): 119-25
The hypervascular nature of hepatocellular carcinoma (HCC) is well characterized. Recent data have suggested that thalidomide possesses antiangiogenic and immunomodulatory activity. Therefore, the authors initiated a study to assess the efficacy and toxicity of thalidomide in patients with advanced HCC as primary and secondary endpoints, respectively.
Help
Trial Administration